NCT06026514 is a Phase 1 clinical trial of B/HPIV3/S-6P in SARS-CoV-2 Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT06026514?

NCT06026514 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT06026514?

Interventions in NCT06026514: B/HPIV3/S-6P.

What condition does NCT06026514 study?

NCT06026514 studies SARS-CoV-2 Infection.

Is NCT06026514 still recruiting?

NCT06026514 is currently completed. Last updated 20 January 2026.

Last reviewed 2026-01-20 · How we verify

NCT06026514

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults

Completed Phase 1 Last updated 20 January 2026

What this trial tests

Phase 1 trial testing B/HPIV3/S-6P in SARS-CoV-2 Infection in 27 participants. Completed in 30 June 2025.

Timeline

18 September 2023

Primary endpoint
16 January 2025

30 June 2025

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	27
Start date	18 September 2023
Primary completion	16 January 2025
Estimated completion	30 June 2025
Sites	1 location across United States

Drugs / interventions tested

B/HPIV3/S-6P — full drug profile →

Conditions studied

SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 18 to 50, any sex, with SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized version of the SARS-CoV-2 spike protein.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms.
Cankat S, Demael MU, Demael MU, Swadling L. · · 2024 · cited 53× · PMID 38148330 · DOI 10.1038/s41423-023-01116-8
Vaccines for Respiratory Viruses-COVID and Beyond.
Rajanala K, Upadhyay AK. · · 2024 · cited 5× · PMID 39204059 · DOI 10.3390/vaccines12080936
Combating respiratory diseases with mucosal vaccines.
Tang PCH, Ling Z, Lee M, King NJC, et al · · 2026 · PMID 41983630 · DOI 10.1128/jvi.00146-26

Verify or expand the search:

Other recruiting trials for SARS-CoV-2 Infection

Currently open trials in the same condition.

NCT07079670 — Safety and Immunogenicity of NVX-CoV2705 · Phase 3 · active not recruiting
NCT05697068 — Intervention to Prevent Household and Community Spread of COVID-19 Among Latinos · NA · active not recruiting
NCT05172011 — Understanding the Long-term Impact of COVID on Children and Families · active not recruiting
NCT05141058 — T Cell Therapy Opposing Novel COVID-19 Infection in Immunocompromised Patients · Phase 1 · recruiting
NCT05046470 — SARS-CoV-2 Transmission in Belgian Primary Schools of the Federation Wallonia - Brussels: An Epidemiological Pilot Study · active not recruiting

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06026514 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 20 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06026514.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing